Literature DB >> 10613722

Apolipoprotein E genotype and the risk of gallbladder disease in pregnancy.

C W Ko1, S A Beresford, B Alderman, G P Jarvik, S J Schulte, B Calhoun, A M Tsuchida, T D Koepsell, S P Lee.   

Abstract

The E4 allele of apolipoprotein E (apoE4) has previously been associated with symptomatic gallstone disease. The aim of this study was to determine if apoE4 is associated with the development of gallbladder sludge and/or stones during pregnancy. We conducted a nested case-control study based on an ongoing cohort study of gallbladder disease in pregnancy. Women in this study receive gallbladder ultrasounds in each trimester of pregnancy. Cases (n = 52) were defined as women with incident gallbladder sludge or stones diagnosed at the third trimester ultrasound. Controls (n = 104) were defined as women without gallbladder sludge or stones on any of 3 study ultrasounds. ApoE genotyping was performed from stored white blood cell pellets. Data were analyzed by stratified analysis and multivariate logistic regression. Cases and controls were similar in baseline characteristics. Forty-two women had sludge, 6 had gallstones, and 4 had both sludge and stones. After adjusting for risk factors such as age, parity, and body mass index, the odds ratio (OR) for the association between heterozygosity or homozygosity for the apoE4 allele and incident gallbladder sludge or stones was 0.91 (95% confidence interval [CI], 0.41-2.02). Further adjustment for family medical history and serum lipid levels did not substantially change these results (OR, 0.73; 95% CI, 0.29-1.82). In conclusion, apoE4 appears to have little or no overall association with the development of new gallbladder sludge or stones in pregnancy. However, an effect could not be ruled out in certain subgroups, such as blacks or women who are homozygous for apoE4.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10613722     DOI: 10.1002/hep.510310105

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  6 in total

1.  ApoB-100, ApoE and CYP7A1 gene polymorphisms in Mexican patients with cholesterol gallstone disease.

Authors:  Jaime Sánchez-Cuén; Maribel Aguilar-Medina; Eliakym Arámbula-Meraz; José Romero-Navarro; Julio Granados; Laura Sicairos-Medina; Rosalío Ramos-Payán
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

2.  Effect of genetic variants related to lipid metabolism as risk factors for cholelithiasis after bariatric surgery in Brazilian population.

Authors:  Sidney Pinheiro-Júnior; Marcela A S Pinhel; Marcelo A Nakazone; Anielli Pinheiro; Gisele F S Amorim; Greiciane M S Florim; Camila M Mazeti; Michele L Gregório; Marina G Moschetta; Gilberto B Brito; Sérgio L A Brienze; Carla B Nonino; Antonio C Brandão; Dorotéia R S Souza
Journal:  Obes Surg       Date:  2012-04       Impact factor: 4.129

3.  Polymorphisms at cholesterol 7alpha-hydroxylase, apolipoproteins B and E and low density lipoprotein receptor genes in patients with gallbladder stone disease.

Authors:  Zhao-Yan Jiang; Tian-Quan Han; Guang-Jun Suo; Dian-Xu Feng; Sheng Chen; Xing-Xing Cai; Zhi-Hong Jiang; Jun Shang; Yi Zhang; Yu Jiang; Sheng-Dao Zhang
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

4.  APOE and FABP2 Polymorphisms and History of Myocardial Infarction, Stroke, Diabetes, and Gallbladder Disease.

Authors:  Ikuko Kato; Susan Land; Jill Barnholtz-Sloan; Richard K Severson
Journal:  Cholesterol       Date:  2011-09-18

5.  The association between apolipoprotein E and gallstone disease: an updated meta-analysis.

Authors:  Lizhuo Li; Xin Qiao; Xia Wang; Di Liu; Qingmu Xue; Lu Han; Fei Dai; Guomin Ma; Zhipeng Yang; Tao Zhang; Shuo Yang; Shikang Cai; Mingyue Gao; Jingyun Yang
Journal:  BMC Med Genet       Date:  2019-06-14       Impact factor: 2.103

6.  A meta-analysis of apolipoprotein E gene ε2/ε3/ε4 polymorphism for gallbladder stone disease.

Authors:  Pei Xue; Wen-Quan Niu; Zhao-Yan Jiang; Min-Hua Zheng; Jian Fei
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.